Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2005 Mar;53(3):241-52.

Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling.

Author information

1
The Churchill Hospital, CRUK Medical Oncology Unit, Oxford Radcliffe Hospitals Trust, Headington, Oxford OX37LJ, UK.

Abstract

This review examines the current evidence for the use of temozolomide in the treatment of solid tumours. The possible molecular and clinical advantages of temozolomide are identified and the molecular mechanism of temozolomide resistance is explored. Attempts to maximise efficacy have led to manipulation of both dosage and drug scheduling and the evidence for the various strategies is reviewed. Finally, the potential role of combination therapy is considered.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center